Last Updated: November 16, 2026

Details for Patent: 9,433,628

« Back to Dashboard


Summary for Patent: 9,433,628
Title:Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Abstract:The present invention refers to a new enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction.Furthermore, the present invention refers to new crystalline forms of cortexolone 17α-propionate and 9,11-dehydro-cortexolone 17α-butanoate.
Inventor(s):Mauro Ajani, Luigi Moro
Assignee: Cassiopea SpA
Application Number:US14/073,928
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,433,628
Patent Claim Types:
see list of patent claims
Composition; Process; Dosage form;
Patent landscape, scope, and claims:

US Patent 9,433,628 (Crystalline Form IV of cortexolone-17α-propionate): Scope, Claim-by-Claim Analysis, and US Patent Landscape

US Drug Patent 9,433,628 is a crystalline-forms and manufacturing-process patent focused on “crystalline form IV” of cortexolone-17α-propionate defined by solid-state characterization (DRX and XRPD peak list) and by a specific crystallization solvent system. The enforceable scope is anchored to (i) achieving the claimed polymorph/solid form and (ii) using the claimed crystallization conditions, plus downstream claim coverage for pharmaceutical compositions containing the form at defined levels in specific dosage formats.


What patents protect crystalline form IV of cortexolone-17α-propionate in the US?

US 9,433,628 protects two main infringement hooks:

  1. Product (solid form) claims: crystalline form IV identified by diffraction fingerprints.
  2. Method (process) claims: formation of crystalline form IV by crystallizing from specific solvent mixtures.
  3. Composition claims: topical or other pharmaceutical compositions containing crystalline form IV, with excipient and content limitations.

How are the “crystalline form IV” product claims defined?

The patent uses characterization-based claim language typical of polymorph estates. The claims tie infringement to whether the material qualifies as “crystalline form IV” based on diffraction measurements:

  • Claim 1: “Crystalline form IV” characterized by DRX as shown in FIG. 28.
  • Claim 2: “Crystalline form IV” characterized by XRPD peaks at about 4.8, 12.9, 14.4, 15.8, 16, 19.3, and 19.5 degrees (2θ).

Practical scope implication: If a competitor produces a solid form that matches the stated diffraction pattern (or the FIG. 28 DRX signature), it can fall within the crystalline form product claims even if the synthesis route differs.

What process features are required for method claims?

The method claims require crystallizing cortexolone-17α-propionate from narrowly defined solvent systems:

  • Claim 3: Crystallizing from propylene glycol/water or polyethylene glycol/water mixture.
  • Claims 4–5: Propylene glycol/water ratio about 1/2 to about 2/1; narrower dependent claim at about 1/1.
  • Claims 6–7: Polyethylene glycol/water ratio about 1/2 to about 2/1; narrower dependent claim at about 1/1.
  • Claims 8–11: Additional dependent crystallization ratios: propylene glycol/water about 1/3 to about 3/1, and then corresponding “prepared by the process” composition coverage in claims 9–13.

Practical scope implication: A generic or alternative manufacturer that can avoid infringement by using a different solvent system may reduce exposure to method claims but still remains exposed under product claims if it makes the same crystalline form.

How do composition claims expand product coverage into formulations?

The patent includes multiple composition claims that incorporate crystalline form IV into a finished dosage or semi-solid matrix.

  • Claim 14: Pharmaceutical composition comprising crystalline form IV, water, and at least one physiologically acceptable excipient.
  • Claim 15: Excipients are limited to specific examples: propylene glycol, cetylic alcohol, glyceryl monostearate, liquid paraffin, or combinations.
  • Claim 16: Further comprising mixed tocopherols and/or polysorbate 80.
  • Claim 17: Composition is in the form of a cream.
  • Claims 18–20: Includes solubilized cortexolone-17α-propionate together with crystalline form IV; combined content ranges:
    • Claim 19: total 0.1 to 2% by weight
    • Claim 20: total 0.2 to 1% by weight
  • Claim 21: crystalline form IV present at 0.1 to 2% by weight.
  • Claims 22–24: Broad additional composition coverage:
    • Claim 22: pharmaceutical composition comprising crystalline form IV of cortexolone-17α-propionate
    • Claim 23: dosage forms include tablet, capsule, powder, pellet, suspension, emulsion, cream, gel, ointment, lotion, paste
    • Claim 24: solid / semi-solid / paste

Practical scope implication: Even if a competitor keeps a different solvent route, they remain exposed if their API contains crystalline form IV and they sell it in the claimed formulations. Claims 14–21 are narrower to excipient sets and content ranges; claims 22–24 are broader on dosage form.


What is the claim scope and infringement risk: form-only vs solvent-only vs formulation-only?

“Crystalline form IV” claims (claims 1–2, 9–13)

These are the highest-risk claims for any manufacturer because they capture the end-state solid rather than the route.

  • If the competitor’s API is crystalline form IV (by DRX/XRPD signature), the supplier and downstream sellers can be exposed.
  • The solvent system limits do not protect a party from form-based product claims.

“Prepared by process” claims (claims 3–8, 9–13)

These create route-specific exposure, but “prepared by” claims can still become broad depending on how the court construes them.

  • If the competitor crystallizes from propylene glycol/water or polyethylene glycol/water within the claimed ratios and produces crystalline form IV, infringement risk rises substantially.
  • Avoiding those solvent systems lowers risk for method claims but not for form claims.

Composition claims (claims 14–24)

Exposure depends on formulation match:

  • Narrow coverage: excipient selection, presence of water, cream form, and content ranges (claims 14–21).
  • Broad coverage: any pharmaceutical composition containing crystalline form IV across many dosage forms (claims 22–24).

What is the scope of DRX/XRPD-based “crystalline form IV” limitations?

DRX FIG. 28 (Claim 1)

Claim 1 is a figure-referenced fingerprint claim. Enforcement typically hinges on whether the accused sample yields a diffraction pattern that corresponds to the FIG. 28 DRX identity.

XRPD peak list (Claim 2)

Claim 2 provides a specific set of peaks:

  • ~4.8°
  • ~12.9°
  • ~14.4°
  • ~15.8°
  • ~16.0°
  • ~19.3°
  • ~19.5°

Scope implication: A competitor that produces a closely related polymorph may still be vulnerable if their XRPD shows peaks falling within the claim’s “about” tolerances. Conversely, a competitor with a different polymorph (or amorphous solid) that omits one or more peaks could reduce risk.


Which solvent systems and ratios are claimed for making crystalline form IV?

Propylene glycol/water (PG/water)

  • Claim 3 + Claim 4: PG/water ratio 1/2 to 2/1.
  • Claim 5: PG/water ratio about 1/1.
  • Claim 8: PG/water ratio 1/3 to 3/1.

Polyethylene glycol/water (PEG/water)

  • Claim 3 + Claim 6: PEG/water ratio 1/2 to 2/1.
  • Claim 7: PEG/water ratio about 1/1.

Scope implication: The process is confined to polyol/water systems. Crystallization using alcohols, glycols with different structures, solvents not listed (or substantially different solvent systems) is outside the express claims, but again form claims remain a backstop.


What formulations are protected by US 9,433,628?

Topical-leaning embodiments in narrow claims

  • Cream (Claim 17)
  • Excipients including propylene glycol, cetylic alcohol, glyceryl monostearate, liquid paraffin
  • Additional excipients: mixed tocopherols and polysorbate 80
  • Must include water (Claim 14)

Dosage form breadth in broader claims

Claims 22–24 extend coverage to many dosage formats, including:

  • tablet, capsule, powder, pellet
  • suspension, emulsion
  • cream, gel, ointment, lotion, paste
  • solid / semi-solid / paste categories

Scope implication: If crystalline form IV appears in any of these product forms, the patent provides potential coverage even outside creams, despite the narrow excipient selections tied to claims 14–21.


How does US 9,433,628 compare with typical crystalline-form patent estates?

This patent follows a common pattern in solid-form portfolios:

  • Fingerprint claims (XRPD/DRX) define the form.
  • Process claims define preparation conditions to create the form.
  • Composition claims create practical downstream leverage against formulation developers and branded/generic product marketers.

Key estate characteristic: Even without knowing other patents in the estate, the claim set already provides both upstream (API manufacturing) and downstream (product formulation) leverage.


What patent expiration and exclusivity timelines apply to US 9,433,628?

No filing, priority, or expiration dates are provided in the prompt, and those are required to calculate patent term, PTA, and any exclusivity interaction. Without those inputs, no enforceable timeline can be stated.


What generic entry risks exist for crystalline form IV?

Risk driver 1: API matching the polymorph

If a generic or ANDA manufacturer obtains crystalline form IV (intentionally or inadvertently) and sells an FDA-approved product containing that form, product claims (1–2, 9–13, 22–24) are directly relevant.

Risk driver 2: Formulation contains crystalline form IV at claimed levels

Even if API is protected only for certain forms, formulation claims add risk by specifying:

  • crystalline form IV content (e.g., 0.1 to 2% by weight in claim 21)
  • total combined content with solubilized cortexolone-17α-propionate (claims 19–20)
  • presence of water and enumerated excipients for certain narrower embodiments

Risk driver 3: Route-based manufacturing falls within claimed solvent systems

If manufacture uses PG/water or PEG/water with the claimed ratios and forms crystalline form IV, method claims create direct exposure.


What patent litigation affects US 9,433,628?

No litigation docket, settlements, or court findings are provided in the prompt, and no reliable litigation status can be listed.


What is the Orange Book status of cortexolone-17α-propionate products containing crystalline form IV?

No Orange Book listings, NDA numbers, or FDA product identifiers are provided. Without those, no Orange Book status can be stated.


Key claim chart: US 9,433,628 infringement checkpoints

Claim Category What must be present / done Primary infringement checkpoint
1 Product (solid form) Crystalline form IV characterized by DRX (FIG. 28) DRX match to FIG. 28
2 Product (solid form) XRPD peaks at ~4.8, 12.9, 14.4, 15.8, 16, 19.3, 19.5 (2θ) XRPD peak presence within “about”
3 Method Crystallize from PG/water or PEG/water mixture Solvent system match
4–5 Method (dependent) PG/water ratio 1/2–2/1; and ~1/1 Ratio within “about” windows
6–7 Method (dependent) PEG/water ratio 1/2–2/1; and ~1/1 Ratio within “about” windows
8 Method (dependent) PG/water ratio 1/3–3/1 Ratio within “about” windows
9–13 Product (prepared by) Crystalline form IV prepared by claims 3–8 Both product and route linkage
14–17 Composition (narrow) Composition with crystalline form IV + water + excipient; cream; listed excipient options Formulation match + excipients + water
18–20 Composition (narrow) Solubilized cortexolone-17α-propionate plus crystalline form IV; total % ranges Content ranges + combination presence
21 Composition (narrow) Crystalline form IV present 0.1–2% by weight Crystal loading
22–24 Composition (broad) Any pharmaceutical composition containing crystalline form IV Inclusion of the crystalline form

Key Takeaways

  • US 9,433,628 is a crystalline form IV patent defined by DRX (FIG. 28) and XRPD peak list, plus a solvent-based crystallization method using propylene glycol/water or polyethylene glycol/water across specified ratios.
  • The core risk is end-state polymorph capture: making or sourcing crystalline form IV can trigger product claims even if the synthesis route differs.
  • Downstream formulation risk is meaningful: the patent covers compositions containing crystalline form IV, including creams with enumerated excipients and broad coverage across many dosage forms.
  • The method claims add an additional enforcement lane against manufacturers using the claimed PG/PEG aqueous crystallization systems.

FAQs

1) Does US 9,433,628 protect crystalline form IV even if prepared with a different solvent than propylene glycol/water or polyethylene glycol/water?

Yes, the claims include product coverage for crystalline form IV defined by DRX/XRPD (claims 1–2), so solvent changes do not eliminate exposure if the produced solid matches the claimed diffraction fingerprint.

2) What is the practical difference between the DRX-based claim (FIG. 28) and the XRPD peak claim?

DRX (claim 1) ties identity to a figure-based diffraction signature, while XRPD (claim 2) specifies a discrete peak set with “about” degrees (2θ). Different testing approaches can support infringement or non-infringement depending on how closely the sample matches the fingerprint.

3) If a competitor uses the claimed PG/water ratio but produces a different polymorph, what happens?

Method claims require crystallization producing “crystalline form IV,” and product claims require the end-state diffraction identity. A different polymorph may avoid form-based infringement, even if the solvent ratio matches.

4) Are cream-specific excipient limitations required for all composition claims?

No. Narrow composition claims (14–21) include water and enumerated excipient examples and cream-specific limitations, while claims 22–24 are broader and cover many dosage forms without requiring those specific excipient lists.

5) Do the content limits (0.1–2% etc.) apply to all composition claims?

No. The numerical content ranges are stated in specific dependent claims (e.g., claims 19–21). Broader composition claims (22–24) cover compositions containing crystalline form IV without repeating those same content thresholds.


References

  1. United States Patent 9,433,628.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,433,628

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sun Pharm WINLEVI clascoterone CREAM;TOPICAL 213433-001 Aug 26, 2020 RX Yes Yes 9,433,628 ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,433,628

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI2007A1616Aug 3, 2007

International Family Members for US Patent 9,433,628

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2503005 ⤷  Start Trial C20250037 Finland ⤷  Start Trial
European Patent Office 2503005 ⤷  Start Trial CA 2025 00047 Denmark ⤷  Start Trial
European Patent Office 2503005 ⤷  Start Trial 301358 Netherlands ⤷  Start Trial
European Patent Office 2503005 ⤷  Start Trial 2025C/551 Belgium ⤷  Start Trial
European Patent Office 2503005 ⤷  Start Trial CR 2025 00047 Denmark ⤷  Start Trial
European Patent Office 2503005 ⤷  Start Trial 854 Finland ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.